The 5th Guangdong-Hong Kong-Macao Greater Bay Area Top 50 Biotech Innovation Enterprises award ceremony was successfully held in Nansha, Guangzhou, on December 29, 2022. The shortlisted companies this year are concentrated in regions such as Guangzhou, Shenzhen, Zhuhai, and Hong Kong, with 54% of these companies having more than half of their workforce in R&D. Companies with a high proportion of R&D personnel are mainly engaged in sectors of biopharmaceuticals and medical devices, accounting for 44% and 36%, respectively. This reflects the Greater Bay Area biotech companies' emphasis on scientific research and innovation.
RECORNA Bio stood out among many participating biopharmaceutical and medical device companies due to its leading RNA editing technology, advanced business model, and excellent talent team, winning the "Emerging Enterprise Award."
The selection of the top 50 biotech innovation companies in the Guangdong-Hong Kong-Macao Greater Bay Area (hereinafter referred to as the "Bay Area Top 50 Selection") is a ranking activity initiated by the China Innovation Industrial Research Institute to recognize outstanding enterprises in the biotechnology industry. The first selection was launched in June 2018 and has been held for five consecutive years, receiving widespread attention and strong support from relevant government departments, venture capital institutions, biotech companies, and media. The judging panel of the Bay Area Top 50 Selection consists of more than 40 professionals from government agencies, third-party research, professional investment, and medical institutions. They comprehensively evaluate the technological innovation and future development prospects of participating companies from three aspects: leading technology application and breakthroughs, market applications, and the valuation and recognition in the capital market. According to the different development stages of enterprises, the Bay Area Top 50 Selection has set up three awards: "Leading Enterprise Award," "Pioneer Enterprise Award," and "Emerging Enterprise Award." In addition, the "Special Awards" and "Most Popular Company Award" are set to honor participants that excel in industry influence, investment value, and company popularity. Among them, the "Emerging Company Award" mainly focuses on unlisted companies in the financing stages of Series A and earlier that have been established for less than three years. The judging panel comprehensively evaluated companies based on industry trends, business models, competitive advantages, and team characteristics and capabilities, and selected the best companies in this category.
RECORNA Bio is an innovative drug development company that develops drugs with its RNA-targeted editing technology for health threats to human that currently have no effective conventional treatment options. This “Emerging Enterprise Award” is an affirmation and encouragement for RECORNA Bio's innovative technology and entrepreneurial activities, which will inspire the company to force ahead in biotechnological innovation. In the future, RECORNA Bio will continue to enhance its R&D capabilities in RNA editing technology, accelerate the advancement of its product pipeline, and consistently lead industry development, and make greater contributions to the growth of biotechnology sector.
